Free Trial
NASDAQ:SCLX

Scilex (SCLX) Stock Price, News & Analysis

$0.97
+0.01 (+1.04%)
(As of 11/1/2024 ET)

About Scilex Stock (NASDAQ:SCLX)

Key Stats

Today's Range
$0.95
$1.01
50-Day Range
$0.79
$1.15
52-Week Range
$0.73
$2.63
Volume
2.08 million shs
Average Volume
2.28 million shs
Market Capitalization
$186.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.33
Consensus Rating
Buy

Company Overview

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Scilex Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
57th Percentile Overall Score

SCLX MarketRank™: 

Scilex scored higher than 57% of companies evaluated by MarketBeat, and ranked 503rd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Scilex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Scilex has only been the subject of 2 research reports in the past 90 days.

  • Read more about Scilex's stock forecast and price target.
  • Earnings Growth

    Earnings for Scilex are expected to grow in the coming year, from ($0.75) to ($0.39) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Scilex is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Scilex is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Scilex's valuation and earnings.
  • Percentage of Shares Shorted

    10.46% of the float of Scilex has been sold short.
  • Short Interest Ratio / Days to Cover

    Scilex has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Scilex has recently increased by 9.75%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Scilex does not currently pay a dividend.

  • Dividend Growth

    Scilex does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.46% of the float of Scilex has been sold short.
  • Short Interest Ratio / Days to Cover

    Scilex has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Scilex has recently increased by 9.75%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Scilex has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Scilex this week, compared to 2 articles on an average week.
  • Search Interest

    5 people have searched for SCLX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Scilex to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Scilex insiders have bought more of their company's stock than they have sold. Specifically, they have bought $95,234.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 8.73% of the stock of Scilex is held by insiders.

  • Percentage Held by Institutions

    69.67% of the stock of Scilex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Scilex's insider trading history.
Receive SCLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scilex and its competitors with MarketBeat's FREE daily newsletter.

SCLX Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Pleasing Signs As A Number Of Insiders Buy Scilex Holding Stock
Scilex announces successful end of Phase II meeting with FDA
See More Headlines

SCLX Stock Analysis - Frequently Asked Questions

Scilex's stock was trading at $2.04 on January 1st, 2024. Since then, SCLX stock has decreased by 52.4% and is now trading at $0.9714.
View the best growth stocks for 2024 here
.

Scilex Holding (NASDAQ:SCLX) announced its earnings results on Tuesday, August, 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.02. The firm had revenue of $16.37 million for the quarter, compared to analysts' expectations of $13.17 million.

Top institutional shareholders of Scilex include Donald L. Hagan LLC (0.07%). Insiders that own company stock include Henry Ji, Jaisim Shah, Jay Chun, Yue Alexander Wu and Stephen Hoi Ma.
View institutional ownership trends
.

Shares of SCLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Scilex investors own include Rigetti Computing (RGTI), Pfizer (PFE), BioNTech (BNTX), Hertz Global (HTZ), Barrick Gold (GOLD), Nikola (NKLA) and BlackBerry (BB).

Company Calendar

Last Earnings
8/13/2024
Today
11/02/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SCLX
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.33
High Stock Price Target
$14.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+1,066.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-114,330,000.00
Net Margins
-233.88%
Pretax Margin
-233.86%

Debt

Sales & Book Value

Annual Sales
$46.74 million
Book Value
($1.10) per share

Miscellaneous

Free Float
175,048,000
Market Cap
$186.30 million
Optionable
Optionable
Beta
1.14
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:SCLX) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners